Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
نویسندگان
چکیده
منابع مشابه
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthc...
متن کاملFirst dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
OBJECTIVES To evaluate the onset of action of alfuzosin once daily (OD) as determined by uroflowmetry early after initial dosing. Alfuzosin OD is an extended-release formulation of a uroselective, alpha1-adrenoreceptor-blocking agent (alpha-blocker) used in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. METHODS This was a randomized, placebo-controlled, two...
متن کاملRe: Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
OBJECTIVES To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). PATIENTS AND METHODS In all, 1522 men at risk of having progression events from LUTS/BPH were randomized to receive alfuzosin 10 mg once daily (759) or placebo (763) for 2 years. Endpoints assessed were...
متن کاملAlfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University CONSULTING EDITOR: Martin A. Rizack, M.D., Ph.D., Rockefeller University CONTRIBUTING EDITOR: Philip D. Hansten, Pharm.D., University of Washington ADVISORY BOARD: Jules Hirsch, M.D., Rockefeller University; James D. Kenney, M.D., Yale University School of Medicine; Gerald L. ...
متن کاملSurgical Options for Benign Prostatic Hyperplasia (BPH)
In 1788 John Hunter first described the pathology of prostatic hyperplasia and its effects on the upper urinary tract. It took a century for the first suprapubic prostatectomy to be carried out in 1887 by AF McGill in Leeds (though Americans tend to claim credit to Fuller in New York in 1894.) The procedure was subsequently p o p u l a r i s e d b y S i r Pe t e r F r e ye r . R e t r o p u b i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Interventions in Aging
سال: 2008
ISSN: 1178-1998
DOI: 10.2147/cia.s3635